These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 26589410)

  • 1. A Novel Method for Preparing Surface-Modified Fluocinolone Acetonide Loaded PLGA Nanoparticles for Ocular Use: In Vitro and In Vivo Evaluations.
    Salama AH; Mahmoud AA; Kamel R
    AAPS PharmSciTech; 2016 Oct; 17(5):1159-72. PubMed ID: 26589410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and in vitro evaluation of surface modified poly(lactide-co-glycolide) nanoparticles with chitosan-4-thiobutylamidine.
    Grabovac V; Bernkop-Schnürch A
    Drug Dev Ind Pharm; 2007 Jul; 33(7):767-74. PubMed ID: 17654025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery.
    Gupta H; Aqil M; Khar RK; Ali A; Bhatnagar A; Mittal G
    Nanomedicine; 2010 Apr; 6(2):324-33. PubMed ID: 19857606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4.
    Wang M; Zhang Y; Feng J; Gu T; Dong Q; Yang X; Sun Y; Wu Y; Chen Y; Kong W
    Int J Nanomedicine; 2013; 8():1141-54. PubMed ID: 23658482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and in vitro evaluation of thienorphine-loaded PLGA nanoparticles.
    Yang Y; Xie XY; Mei XG
    Drug Deliv; 2016; 23(3):787-93. PubMed ID: 24870204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing.
    Zeng P; Xu Y; Zeng C; Ren H; Peng M
    Int J Pharm; 2011 Aug; 415(1-2):259-66. PubMed ID: 21645597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting.
    Chung YI; Kim JC; Kim YH; Tae G; Lee SY; Kim K; Kwon IC
    J Control Release; 2010 May; 143(3):374-82. PubMed ID: 20109508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration.
    Zhang X; Sun M; Zheng A; Cao D; Bi Y; Sun J
    Eur J Pharm Sci; 2012 Apr; 45(5):632-8. PubMed ID: 22248882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
    Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
    Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of chitosan-coated poly(lactic-co-glycolic acid) nanoparticles for improving oral absorption of 7-ethyl-10-hydroxycamptothecin.
    Guo M; Rong WT; Hou J; Wang DF; Lu Y; Wang Y; Yu SQ; Xu Q
    Nanotechnology; 2013 Jun; 24(24):245101. PubMed ID: 23702815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization.
    Cun D; Jensen DK; Maltesen MJ; Bunker M; Whiteside P; Scurr D; Foged C; Nielsen HM
    Eur J Pharm Biopharm; 2011 Jan; 77(1):26-35. PubMed ID: 21093589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and characterization of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles as a sustained-release anticancer drug delivery system.
    Amjadi I; Rabiee M; Hosseini MS; Mozafari M
    Appl Biochem Biotechnol; 2012 Nov; 168(6):1434-47. PubMed ID: 22976852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLGA:poloxamer blend micro- and nanoparticles as controlled release systems for synthetic proangiogenic factors.
    Parajó Y; d'Angelo I; Horváth A; Vantus T; György K; Welle A; Garcia-Fuentes M; Alonso MJ
    Eur J Pharm Sci; 2010 Dec; 41(5):644-9. PubMed ID: 20869438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment.
    Feng SS; Zeng W; Teng Lim Y; Zhao L; Yin Win K; Oakley R; Hin Teoh S; Hang Lee RC; Pan S
    Nanomedicine (Lond); 2007 Jun; 2(3):333-44. PubMed ID: 17716178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA.
    Nair K L; Jagadeeshan S; Nair SA; Kumar GS
    Int J Nanomedicine; 2011; 6():1685-97. PubMed ID: 21980233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier.
    Chen YC; Hsieh WY; Lee WF; Zeng DT
    J Biomater Appl; 2013 Mar; 27(7):909-22. PubMed ID: 22207601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration.
    Tahara K; Miyazaki Y; Kawashima Y; Kreuter J; Yamamoto H
    Eur J Pharm Biopharm; 2011 Jan; 77(1):84-8. PubMed ID: 21074612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Formulation and process optimization of doxorubicin-loaded PLGA nanoparticles and its in vitro release].
    Li JL; Zheng CL; Liu JP; Zhu JB
    Yao Xue Xue Bao; 2013 May; 48(5):759-66. PubMed ID: 23888702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.
    Lee C; Choi JS; Kim I; Oh KT; Lee ES; Park ES; Lee KC; Youn YS
    Int J Nanomedicine; 2013; 8():2975-83. PubMed ID: 23976850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation.
    Mehta AK; Yadav KS; Sawant KK
    Curr Drug Deliv; 2007 Jul; 4(3):185-93. PubMed ID: 17627492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.